Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFP Prime-Boost Protocol
NCT00093548Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
A Phase 2 trial of Alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim in hepatocellular carcinoma (HCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Status: withdrawn.
02
Drugs
Alpha fetoprotein adenoviral vector vaccinealpha fetoprotein plasmid DNA vaccinesargramostim
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00093548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093548.